Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC, known as MSD outside the United States and Canada, is a research-intensive biopharmaceutical company developing innovative medicines and vaccines for the prevention and treatment of disease in people and animals. Operating for more than 130 years, the company works across pharmaceutical research and development, vaccine development, biopharmaceuticals, drug discovery and pipeline development, and veterinary science. Its stated aspiration is to be the premier research-intensive biopharmaceutical company in its field.

The scientific record is substantive. MSD developed Streptomycin, a breakthrough medicine that helped reduce tuberculosis deaths by nearly 50% by 1950. The company currently reports one of the most diverse pipelines in its history, directed at serious health concerns in both prevention and treatment. The governing principle is to follow the science where it can make the greatest difference; MSD describes itself as guided by the philosophy that medicine is for the people, not for the profits.

MSD Animal Health extends this work to veterinary solutions - supporting the bond between people and pets, protecting public health, ensuring food safety, and increasing protein supplies worldwide. The company's presence spans the United States, Canada, and global markets, covering the pharmaceuticals, biopharmaceuticals, healthcare, vaccines, animal health, veterinary, food safety, and public health sectors.

For professionals in pharmaceutical R&D, vaccinology, drug discovery, and veterinary science, the appeal is a long-standing legacy of inventing life-changing therapies combined with an unusually broad and active pipeline.